Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy
- 30 November 2003
- journal article
- clinical trial
- Published by Elsevier BV in American Heart Journal
- Vol. 146 (5), 854
- https://doi.org/10.1016/s0002-8703(03)00415-0
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- The Antianginal Drug Trimetazidine Shifts Cardiac Energy Metabolism From Fatty Acid Oxidation to Glucose Oxidation by Inhibiting Mitochondrial Long-Chain 3-Ketoacyl Coenzyme A ThiolaseCirculation Research, 2000
- Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery diseaseThe American Journal of Cardiology, 1998
- Effects of trimetazidine on pHi regulation in the rat isolated ventricular myocyteBritish Journal of Pharmacology, 1996
- Myocardial substrate metabolism: Implications for diabetic CardiomyopathyJournal of Molecular and Cellular Cardiology, 1995
- Some Biochemical Aspects of the Protective Effect of Trimetazidine on Rat Cardiomyocytes During Hypoxia and ReoxygenationJournal of Molecular and Cellular Cardiology, 1994
- Metabolic management of ischaemic heart diseaseEuropean Heart Journal, 1993
- Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathyEuropean Heart Journal, 1990
- Internal pH, Na+, and Ca2+ regulation by trimetazidine during cardiac cell acidosisCardiovascular Drugs and Therapy, 1988
- Effect of trimetazidine on membrane damage induced by oxygen free radicals in human red cells.British Journal of Clinical Pharmacology, 1985
- Effect of myocardial ischaemia and antilipolytic agents on lipolysis and fatty acid metabolism in the in situ dog heartScandinavian Journal of Clinical and Laboratory Investigation, 1979